Difference between revisions of "Healthcare system reform"
Ruthdonners (talk | contribs) m (New page: '''Work under construction. In case you have any questions, additions or comments, please do not edit these pages, but you are more than welcome to [mailto:ruthdonners@hotmail.com contact ...) |
Murat.akguc (talk | contribs) |
||
| Line 4: | Line 4: | ||
==Developments in time== | ==Developments in time== | ||
===2010-2015=== | ===2010-2015=== | ||
At the end of first decade of new millennium, innovation in the healthcare system is primarily dominated by multinational companies. Regulators had generally seen their role as being limited to that of framing regulations to deal with potential safety and efficacy issues, and ensuring compliance with these regulations. Around 2010 after the 2008 financial crisis, instead of seeing themselves as passive responders to events, regulators began to see their role in a much more proactive way. In line with “new governance” agendas and linked to globalisation | |||
initiatives, discussions began to take place within regulatory bodies about their role in stimulating | |||
changes in the processes and outcomes of health care innovation. | |||
===2015-2020=== | ===2015-2020=== | ||
===2020-2025=== | ===2020-2025=== | ||
Revision as of 16:08, 8 October 2009
Work under construction. In case you have any questions, additions or comments, please do not edit these pages, but you are more than welcome to contact us.
Scenario wherein the healthcare system is more integrated, shorter lines between pharma, medicine, insurance companies
Developments in time
2010-2015
At the end of first decade of new millennium, innovation in the healthcare system is primarily dominated by multinational companies. Regulators had generally seen their role as being limited to that of framing regulations to deal with potential safety and efficacy issues, and ensuring compliance with these regulations. Around 2010 after the 2008 financial crisis, instead of seeing themselves as passive responders to events, regulators began to see their role in a much more proactive way. In line with “new governance” agendas and linked to globalisation initiatives, discussions began to take place within regulatory bodies about their role in stimulating changes in the processes and outcomes of health care innovation.